EGFR and non-small cell lung carcinoma: In the Randomized phase III double-blind trial in adjuvant NSCLC with Tarceva (RADIANT trial) patients with resected stage IB to IIIA NSCLC which are positive for EGFR detected by FISH or IHC are being enrolled.